Salisbury Foundation Trust

FOI_5066

Internal Reference Number: FOI_5066

Date Request Received: 21/05/2019 13:15:28

Date Request Replied To: 28/06/2019 11:52:01

This response was sent via: By Email

Request Summary: Cancer treatments over the past 6 months, involvement with clinical trials

Request Category: Private Individuals

 
Question Number 1:
Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell lung cancer (NSCLC) with the following:

Paclitaxel
Gemcitabine
Osimertinib
Carboplatin and Pemetrexed
Cisplatin and Pemetrexed
Pembrolizumab monotherapy
Pembrolizumab in combination
Atezolizumab
Nivolumab
Other active systemic anti-cancer therapy
 
Answer To Question 1:
Paclitaxel 0
Gemcitabine 0
Osimertinib 0
Carboplatin and Pemetrexed 5
Cisplatin and Pemetrexed <5
Pembrolizumab monotherapy 0
Pembrolizumab in combination <5
Atezolizumab 6
Nivolumab 0
Other active systemic anti-cancer therapy 44


Please note that it is Trust policy not to disclose potentially patient identifiable information, thus if there are less than 5 patients we will specify only '<5'.
 
Question Number 2:
Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Non Small Cell Lung cancer patients ?
 
Answer To Question 2:
yes
 
Question Number 3:
If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
 
Answer To Question 3:
Stratified Medicine Programme
SMP2 – 68 patients . Trial opened August 2015

 
Question Number 4:
Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal cancer (CRC) with the following:

Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Aflibercept
Bevacizumab
Ramucirumab
Regorafenib
Sorafenib
Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)
 
Answer To Question 4:
Cetuximab not in combination with FOLFIRI or FOLFOX 0
Cetuximab in combination with FOLFIRI 0
Cetuximab in combination with FOLFOX <5
Panitumumab not in combination with FOLFIRI or FOLFOX 0
Panitumumab in combination with FOLFIRI <5
Panitumumab in combination with FOLFOX 12
Nivolumab 0
Aflibercept 0
Bevacizumab 0
Ramucirumab 0
Regorafenib 0
Sorafenib 0
Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU) 83

 
Question Number 5:
Does your Health Trust participate in any ongoing clinicals trials for the treatment of Colorectal cancer patients ?
 
Answer To Question 5:
Yes
 
Question Number 6:
If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
 
Answer To Question 6:
TRACC . Tracking Mutations in cell free tumour DNA to predict relapse in early colorectal cancer
30 patients . Trial opened January 2018

Add aspirin. A Phase III double blind placebo controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. (Colorectal cohort)
15 patients . Trial opened June 2015

TRIGGER
Magnetic resonance Tumour regression grade (mrTRG)as a novel biomarker to stratify management of good and poor responders to chemoradiotherapy ;A rectal cancer multicentre randomised control trial to avoid surgery with watch and wait or intensify treatment according to mrTRG
<5 patients. Trial opened July 2016

CIPHER
Prospective observational –colostomy and loop ileostomy stoma formation
28 patients. Trial opened Nov 2017

IMPRESS
Improving radical treatment through MRI evaluation of pelvic sigmoid cancers
34 patients. Trial opened July 2017

SERENADE
Screening for synchronous metastases in colorectal cancer with DW-MRI
49 patients. Trial opened October 2015

HIP
Prospective, non-randomised observational study, for rectal cancer patients undergoing either Hartmann’s procedure or intersphincteric APE, to determine the use of each surgical technique and their associated complication rate up to 90 days post op.
5 patients Trial opened September 2016
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values